Compositions and methods for modulating c-kit and PDGFR receptors
The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.
1. A compound of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein:
Y is CR and Z is N;
L is NR—C(O), C(O)NR, C(O)NRC(O)NR, NRC(O)NRC(O), NRC(S)NRCO, NRS(O) 0-2 or NRCONRS(O) 0-2 ;
R 1 is halo, (CR 2 ) k NR 7 R 8 , (CR 2 ) k OR 9 , (CR 2 ) k SR 9 , aryl or heteroaryl; or R 1 is C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein each of said C 1-6 alkyl and C 2-6 alkenyl is optionally substituted with ureayl, guanidyl, O(C 1-6 alkyl), or optionally substituted with C 3-7 cycloalkyl, phenyl, or heteroaryl, said phenyl is further optionally substituted with halo or an optionally halogenated C 1-6 alkyl;
R 2 is (CR 2 ) 1-4 OR 9 , (CR 2 ) 1-4 NR 7 R 8 or aryl; or R 2 is C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein said C 1-6 alkyl is optionally substituted with phenyl, or heteroaryl;
R 3 is halo or C 1-6 alkyl;
R 4 is (CR 2 ) k R 6 , dihydroindenyl, C 1-6 alkyl or (CR 2 ) k OR 9 ;
R 5 is H, halo or C 1-6 alkyl;
R 6 is C 3-7 cycloalkyl, aryl, heterocyclic ring or heteroaryl, each of which is optionally substituted with halo, cyano, nitro, NR 7 R 8 , NRCOR 7 , (CR 2 ) p OR 9′ , (CR 2 ) p R 10 , or a C 1-6 alkyl optionally substituted with halo, hydroxyl, C 1-6 alkoxy or cyano;
R 9′ is H, an optionally halogenated C 1-6 alkyl or (CR 2 ) p R 10 ;
R 10 is C 3-7 cycloalkyl, aryl, 5-7 membered heterocyclic ring, or heteroaryl, each of which is optionally substituted with halo, cyano, nitro, NR 7 R 8 , NRCOR 7 , NRC(O)(CR 2 ) p NR 7 R 8 (7), NRCONR(CR 2 ) p NR 7 R 8 , OR 9 , or C 1-6 alkyl optionally substituted with hydroxyl;
R 7 , R 8 and R 9 are independently H or C 1-6 alkyl; or R 7 and R 8 together with N in each NR 7 R 8 may form a 5-7 membered heterocyclic ring;
each R is H or C 1-6 alkyl;
k is 0-6; and
n is 0-2;
provided L is C(O)NRC(O)NR, NRC(O)NRC(O), NRC(S)NRCO or NRCONRS(O) 0-2 when R 1 is halo or (CR 2 ) k NR 7 R 8 and R 2 is C 1-6 alkyl.
2. The compound of claim 1 , wherein Y is CH.
3. The compound of claim 1 , wherein R 1 is halo, (CR 2 ) 1-4 NR 7 R 8 , (CR 2 ) k OR 9 , (CR 2 ) k SR 9 , phenyl, pyridyl or pyrimidinyl; or R 1 is C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with ureayl, guanidyl, O(C 1-6 alkyl), or optionally substituted with C 3-7 cycloalkyl, phenyl, imidazolyl, thiazolyl, pyrimidinyl, furanyl or pyridyl, said phenyl is further optionally substituted with halo or an optionally halogenated C 1-6 alkyl;
R 7 , R 8 and R 9 are independently H or C 1-6 alkyl; or R 7 and R 8 together with N may form morpholinyl or piperazinyl; and
each k is 0-4.
4. The compound of claim 1 , wherein R 2 is (CR 2 ) 1-4 OR 9 , (CR 2 ) 1-4 NR 7 R 8 or phenyl; or R 2 is C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with phenyl, pyridyl or pyrimidinyl; and
R 7 , R 8 and R 9 are independently H or C 1-6 alkyl; or R 7 and R 8 together with N may form morpholinyl or piperazinyl.
5. The compound of claim 1 , wherein n is 1; and R 3 is methyl or halo.
6. The compound of claim 1 , wherein R 4 is C 1-6 alkyl.
7. The compound of claim 1 , wherein R 4 is dihydroindenyl, (CR 2 ) k R 6 or (CR 2 ) k O(C 1-6 alkyl);
R 6 is phenyl, C 3-7 cycloalkyl, thiazolyl, thienyl, piperidinyl, piperazinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, furanyl, pyrrolyl, dihydropyrrolyl, oxazolyl, isoxazolyl, triazolyl, azetidinyl, thiadiazolyl, benzimidazolyl, quinolinyl, tetrahydroquinolinyl, benzothiazolyl, benzothiophenyl, benzodioxolyl, indazolyl, indolyl, or dihydrobenzofuranyl, each of which is optionally substituted with halo, cyano, nitro, NR 7 R 8 , NRCOR 7 , (CR 2 ) p OR 9′ , (CR 2 ) p R 10 , or a C 1-6 alkyl optionally substituted with halo, hydroxyl, C 1-6 alkoxy or cyano; and
R 7 , R 8 , R 9′ , R 10 , R and p are as defined in claim 1 ; and
k is 0-4.
8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable excipient.
9. The compound of claim 1 , wherein R 5 is H.
10. The compound of claim 1 , wherein said compound is of Formula (2):
wherein R 1 , R 2 , R 3 , R 4 and L are as defined in claim 1 .
11. The compound of claim 10 , wherein R 1 , R 2 and R 3 are methyl.
12. The compound of claim 10 , wherein R 4 is C 1-6 alkyl.
13. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 10 and a pharmaceutically acceptable excipient.
15. The compound of claim 1 , wherein said compound is selected from the group consisting of:
16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 15 and a pharmaceutically acceptable excipient.
17. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 13 and a pharmaceutically acceptable excipient.